Clinical Trials Logo

Hyperkalemia clinical trials

View clinical trials related to Hyperkalemia.

Filter by:

NCT ID: NCT03229265 Completed - Kidney Transplant Clinical Trials

Pharmacokinetic Study of Tacrolimus and Mycophenolate Mofetil in Kidney Transplant Recipients With Hyperkalemia Receiving Patiromer

Start date: August 1, 2017
Phase: Phase 4
Study type: Interventional

Hyperkalemia (high potassium in blood) is a common condition found in kidney transplant patients. Risk factors include poor kidney function and exposure to various drugs. Regardless of the causes, current treatment options are limited. Previously, the only available potassium binder for lowering potassium in the blood is sodium polystyrene sulfonate, which has unknown drug interaction profile with transplant medications. Patiromer is a newly approved potassium binder indicated for the treatment of hyperkalemia. Kidney transplant patients with hyperkalemia may benefit from patiromer. However, the interaction of patiromer and transplant medications has not been studied. The goal of this study is to look into the drug interactions between patiromer and transplant medications.

NCT ID: NCT03183778 Completed - Clinical trials for Chronic Kidney Diseases

Use of Patiromer to Transition Chronic Kidney Disease Patients With Hyperkalemia to a Plant-rich Diet.

Start date: March 12, 2018
Phase: Phase 4
Study type: Interventional

The purpose of this proof-of-concept controlled-feeding study is to determine whether patiromer (Veltassa®, Relypsa, Inc., Redwood City, CA) can be used to maintain normal serum potassium concentrations in chronic kidney disease (CKD) patients who are transitioned to a plant-rich diet.

NCT ID: NCT03172702 Completed - Hyperkalemia Clinical Trials

Open-label Safety of Sodium Zirconium Cyclosilicate for up to 12 Months in Japanese Subjects With Hyperkalemia

Start date: September 4, 2017
Phase: Phase 3
Study type: Interventional

The Open-Label Maintenance Study contains an Correction Phase, in which subjects will be dosed with ZS 10 g three times daily (tid) for 24 to 72 hours, followed by a 12-month long-term Maintenance Phase.

NCT ID: NCT03161977 Completed - Hyperkalemia Clinical Trials

The Effect of Mannitol on the Serum Potassium During Craniotomy

Start date: January 1, 2017
Phase: N/A
Study type: Observational

This is an observational study designed to research the effect of mannitol on the concentration of intraoperative serum potassium in patients undergoing craniotomy, and to guide the safe use of mannitol during craniotomy.

NCT ID: NCT03127644 Completed - Hyperkalemia Clinical Trials

ZS Ph2/3 Dose-response Study in Japan

Start date: June 14, 2017
Phase: Phase 2/Phase 3
Study type: Interventional

To assess efficacy of 5 g three times daily (TID) and 10 g TID ZS versus placebo in Japanese patients with hyperkalemia (serum potassium [S-K] ≥ 5.1 mmol/L and ≤ 6.5 mmol/L).

NCT ID: NCT03071263 Completed - Hyperkalemia Clinical Trials

Spironolactone With Patiromer in the Treatment of Resistant Hypertension in Chronic Kidney Disease

AMBER
Start date: January 23, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if patiromer treatment in chronic kidney disease (CKD) subjects receiving spironolactone for the treatment of resistant hypertension will result in more persistent use of spironolactone through prevention of hyperkalemia and lead to improved blood pressure control compared with treatment with spironolactone alone (placebo).

NCT ID: NCT02933450 Completed - Clinical trials for Kidney Failure, Chronic

Relypsa For ED Acute Hyperkalemia Control and Reduction (REDUCE)

Start date: August 2016
Phase: Phase 4
Study type: Interventional

The Investigator hypothesize that a single dose of patiromer will lower serum potassium levels in less than 6hrs. Since a dosage of 30g/day for a period of 4 weeks has been studied in at least two multicenter randomized controlled trials, the Investigator further hypothesize that a single dose of 25.2g of patiromer will be well tolerated in hyperkalemic patients in the Emergency Department setting. The FDA approved dosage of 25.2g is appropriate for this study because the research staff will enroll patients with moderate (K greater than 6 mEq/L) to severe hyperkalemia, and the higher dosage has typically been used in this population for more effective control.

NCT ID: NCT02875834 Completed - Hyperkalemia Clinical Trials

A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia

HARMONIZE GL
Start date: March 3, 2017
Phase: Phase 3
Study type: Interventional

To evaluate the efficacy of two different doses (5 and 10 g) of ZS orally administered once daily (qd) vs placebo in maintaining normokalemia in initially hyperkalemic patients having achieved normokalemia following two days of initial ZS therapy (10g TID).

NCT ID: NCT02825784 Completed - Clinical trials for Chronic Kidney Disease

A Multicenter Study to Evaluate the Nutritional Suitability of Renastart

Renastart
Start date: January 6, 2017
Phase: N/A
Study type: Interventional

A multicenter, open label, uncontrolled study to evaluate the acceptability, tolerability, and nutritional suitability of a medical food (Renastart, Vitaflo International Ltd) specially formulated to meet the unique nutritional needs of children from birth to 10 years with chronic kidney disease (CKD)

NCT ID: NCT02694744 Completed - Hyperkalemia Clinical Trials

Patiromer With or Without Food for the Treatment of Hyperkalemia

TOURMALINE
Start date: February 2016
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of patiromer administered once daily (QD) when given with food compared to without food (experimental treatment group) for the treatment of hyperkalemia (high potassium in the blood).